Lupin Somerset voluntarily recalled Morphine Sulfate Extended-Release Tablets, 60 mg, due to failed impurities and degradation specifications, the FDA said on April 10, 2019. The recall affects 10,284 bottles distributed nationwide.
How to tell if you have it
- Brand: Lupin Somerset
- Product: Morphine Sulfate Extended-Release Tablets, 60 mg, 100-count bottles
- NDC: 43386-542-01
- Lot codes: S700222 (Exp. Apr 30 2019), S800233 (Exp. Feb 29 2020)
- Manufacturer: Novel Laboratories, Inc.
- Units affected: 10,284 bottles
The hazard
The recall was initiated because the Morphine Sulfate Extended-Release Tablets failed impurities and degradation specifications. The FDA classified this as a Class III recall.
Context
GovInfoNow's records show Lupin Somerset has had 8 other recalls on record since May 24, 2018. Other recent recalls of similar products include Gavilyte-N Packets (March 19, 2019), Fluocinolone Acetonide Topical Solution (Jan. 15, 2019), and Nitrofurantoin Oral Suspension (Dec. 21, 2018). Other recent recalls of similar products include Somerset Therapeutics Dexamethasone Injection (Feb. 4, 2026), Lupin Sertraline Tablets (Nov. 5, 2025), and Lupin Ganirelix Acetate Injection (Nov. 13, 2025).